Please login to the form below

Not currently logged in
Email:
Password:

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

Belgium biopharmaceutical company Ablynx has appointed Dr Robert Zeldin to replace Dr Dominique Tersago as its chief medical officer.

A clinical immunologist, Zeldin has more than 15 years combined regulatory and industry experience, having previously served at Merck & Co, Novartis and the FDA.

He has held senior level clinical development positions within pharma and prior to his move into the industry, Zeldin spent several years in private practice and two years as a medical officer at the FDA's Center for Biologics Evaluation and Research.

Ablynx CEO Dr Edwin Moses said: “We are very pleased that someone with Robert's track record and experience is joining Ablynx as chief medical officer.

“Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.”

3rd December 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

CBC
Building Europe’s next breakthrough biotechs
Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK...
Tactful screening & participant sensitivity
Screening participants can involve asking personal questions that could be perceived as intrusive. Here CMR explores the implications of such lines of questioning....
Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...

Infographics